JPH0534342B2 - - Google Patents
Info
- Publication number
- JPH0534342B2 JPH0534342B2 JP57189253A JP18925382A JPH0534342B2 JP H0534342 B2 JPH0534342 B2 JP H0534342B2 JP 57189253 A JP57189253 A JP 57189253A JP 18925382 A JP18925382 A JP 18925382A JP H0534342 B2 JPH0534342 B2 JP H0534342B2
- Authority
- JP
- Japan
- Prior art keywords
- streptococcus
- active fraction
- bacterial
- bacterial cells
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 241000194017 Streptococcus Species 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000194031 Enterococcus faecium Species 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 241000194049 Streptococcus equinus Species 0.000 claims description 4
- 241000194024 Streptococcus salivarius Species 0.000 claims description 3
- 229940115921 streptococcus equinus Drugs 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Compounds Of Unknown Constitution (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57189253A JPS5980609A (ja) | 1982-10-29 | 1982-10-29 | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57189253A JPS5980609A (ja) | 1982-10-29 | 1982-10-29 | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5980609A JPS5980609A (ja) | 1984-05-10 |
| JPH0534342B2 true JPH0534342B2 (de) | 1993-05-21 |
Family
ID=16238191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57189253A Granted JPS5980609A (ja) | 1982-10-29 | 1982-10-29 | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5980609A (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980610A (ja) * | 1982-10-29 | 1984-05-10 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
| JPS59109181A (ja) * | 1982-12-16 | 1984-06-23 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980610A (ja) * | 1982-10-29 | 1984-05-10 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
-
1982
- 1982-10-29 JP JP57189253A patent/JPS5980609A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980610A (ja) * | 1982-10-29 | 1984-05-10 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5980609A (ja) | 1984-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0564127B2 (de) | ||
| EP0181170B1 (de) | Hypercholesterolemisch aktive Produkte | |
| US4797278A (en) | Hypocholesterolemically and/or hypotriglyceridemically active products and their use | |
| EP0228861B1 (de) | Mittel zur Senkung des Dimethylnitrosoaminespiegels | |
| JPH0142280B2 (de) | ||
| JPWO2005077390A1 (ja) | 血糖値低下剤、糖尿病治療・予防剤及びその製造方法 | |
| JPS58131917A (ja) | 抗動脈硬化剤 | |
| JPH0534342B2 (de) | ||
| JPS6320807B2 (de) | ||
| JPH0365362B2 (de) | ||
| JP2969017B2 (ja) | 感染防御剤 | |
| EP0196858B1 (de) | Mittel zur Verbesserung der Lebensfunktion und Mittel zur Senkung des Blutdrucks | |
| JPS5980610A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| JPH0566370B2 (de) | ||
| US4833129A (en) | Hypocholesterolemically and/or hypotriglyceridemically active RNA fractions | |
| JP2841237B2 (ja) | 血圧降下作用を有する菌体水抽出物を有効成分とする血圧降下剤 | |
| JPS59109180A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| JPS59109181A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| JPH1029946A (ja) | 液性免疫回復剤 | |
| JPH06116155A (ja) | 血清コレステロール低下剤 | |
| JPH05229954A (ja) | 白血球減少治療剤 | |
| JPH07138169A (ja) | 抗膀胱炎用剤 | |
| JPS59109182A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| JP2003327538A (ja) | 免疫機能改善剤 |